Meditech begins second stage of Phase II
Monday, 06 December, 2004
Meditech Research (ASX:MTR) has commenced the second stage of its Phase II trial of HyCAMP, its proprietary formulation of chemotherapeutic drug irinotecan in combination with hyaluronic acid.
The trial will examine the safety and efficacy of HyCAMP and compare it to irinotecan alone in 86 patients previously treated with 5-fluorouracil. The trial is expected to be completed in mid-2006.
In an earlier uncontrolled study testing HyCAMP in twelve patients, the treatment showed similar efficacy with improved safety.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...